skip to main content

Diabetes chronic kidney disease follow-up — USMLE Step 3 MCQ

Instant feedback + full explanation. One question, done properly.

HardInternal Medicine (chronic management)Diabetes chronic kidney disease follow-upUSMLE Step 3

A 61-year-old with type 2 diabetes and CKD takes maximally tolerated losartan and empagliflozin. eGFR is 46 mL/min/1.73 m2, urine albumin-creatinine ratio remains 520 mg/g, potassium is 4.5 mEq/L, and blood pressure and A1c are at individualized targets. Which addition most directly reduces further kidney and cardiovascular risk?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Add finerenone with potassium monitoring to target persistent albuminuria

The best answer is “Add finerenone with potassium monitoring to target persistent albuminuria”. Persistent albuminuric diabetic CKD despite renin-angiotensin blockade and SGLT2 inhibition is an indication for finerenone when eGFR and potassium permit. Potassium is checked after initiation and periodically because hyperkalemia remains the principal risk. Steroidal mineralocorticoid antagonists can treat resistant hypertension or heart failure but do not have the same diabetic-CKD outcome evidence, and withdrawing losartan or empagliflozin would discard complementary kidney protection.

Reference: ADA Standards of Care: Chronic Kidney Disease and Risk Management: https://diabetesjournals.org/care/article/49/Supplement_1/S246/163916/11-Chronic-Kidney-Disease-and-Risk-Management